Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;22(3):279-288.
doi: 10.1177/17407745241304355. Epub 2024 Dec 29.

Concordance between clinical trial data use request proposals and corresponding publications: A cross-sectional study

Affiliations

Concordance between clinical trial data use request proposals and corresponding publications: A cross-sectional study

Enrique Vazquez et al. Clin Trials. 2025 Jun.

Abstract

Background/AimsThe reuse of clinical trial data available through data-sharing platforms has grown over the past decade. Several prominent clinical data-sharing platforms require researchers to submit formal research proposals before granting data access, providing an opportunity to evaluate how published analyses compare with initially proposed aims. We evaluated the concordance between the included trials, study objectives, endpoints, and statistical methods specified in researchers' clinical trial data use request proposals to four clinical data-sharing platforms and their corresponding publications.MethodsWe identified all unique data request proposals with at least one corresponding peer-reviewed publication as of 31 March 2023 on four prominent clinical trial data sharing request platforms (Vivli, ClinicalStudyDataRequest.com, the Yale Open Data Access Project, and Supporting Open Access to Researchers-Bristol Myers Squibb). When data requests had multiple publications, we treated each publication-request pair as a unit. For each pair, the trials requested and analyzed were classified as fully concordant, discordant, or unclear, whereas the study objectives, primary and secondary endpoints, and statistical methods were classified as fully concordant, partially concordant, discordant, or unclear. For Vivli, ClinicalStudyDataRequest.com, and Supporting Open Access to Researchers-Bristol Myers Squibb, endpoints of publication-request pairs were not compared because the data request proposals on these platforms do not consistently report this information.ResultsOf 117 Vivli publication-request pairs, 76 (65.0%) were fully concordant for the trials requested and analyzed, 61 (52.1%) for study objectives, and 57 (48.7%) for statistical methods; 35 (29.9%) pairs were fully concordant across the 3 characteristics reported by all platforms. Of 106 ClinicalStudyDataRequest.com publication-request pairs, 66 (62.3%) were fully concordant for the trials requested and analyzed, 41 (38.7%) for study objectives, and 35 (33.0%) for statistical methods; 20 (18.9%) pairs were fully concordant across the 3 characteristics. Of 65 Yale Open Data Access Project publication-request pairs, 35 (53.8%) were fully concordant for the trials requested and analyzed, 44 (67.7%) for primary study objectives, and 25 (38.5%) for statistical methods; 15 (23.1%) pairs were fully concordant across the 3 characteristics. In addition, 26 (40.0%) and 2 (3.1%) Yale Open Data Access Project publication-request pairs were concordant for primary and secondary endpoints, respectively, such that only one (1.5%) Yale Open Data Access Project publication-request pair was fully concordant across all five characteristics reported. Of three Supporting Open Access to Researchers-Bristol Myers Squibb publication-request pairs, one (33.3%) was fully concordant for the trials requested and analyzed, two (66.6%) for primary study objectives, and two (66.6%) for statistical methods; one (33.3%) pair was fully concordant across all three characteristics reported by all platforms.ConclusionAcross four clinical data sharing platforms, data request proposals were often discordant with their corresponding publications, with only 25% concordant across all three key proposal characteristics reported by each platform. Opportunities exist for investigators to describe any data-sharing request proposal deviations in their publications and for platforms to enhance the reporting of key study characteristic specifications.

Keywords: Clinical trials; data sharing; transparency.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.S.R., C.P.G., J.D.R., H.M.K., and J.D.W. are members of the YODA Project leadership team and receive support from Johnson & Johnson to support data sharing through the YODA project. J.S.R. is supported by the FDA, Arnold Ventures, AHRQ, and NHLBI and was an expert witness at the request of Relator’s attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc. that was settled in September 2022. C.P.G. has received research funding from the NCCN Foundation (Astra-Zeneca) and Genentech. K.C. and S.B. are current employees and shareholders of Johnson & Johnson. J.D.R receives support from the FDA and Arnold Ventures. J.W. is a former employee and current shareholder of Johnson & Johnson and an Independent Board of Director and Shareholder for Becton Dickinson and Structure Therapeutics. J.W. is also a consultant for Galapagos NV. H.M.K. received options for Element Science and Identifeye and payments from F-Prime for advisory roles. He is a co-founder of and holds equity in Hugo Health, Refactor Health, and ENSIGHT-AI. He is associated with research contracts through Yale University from Janssen, Kenvue, and Pfizer. J.D.W. is supported by the FDA and Arnold Ventures. J.D.W. previously served as a consultant to Hagens Berman Sobol Shapiro LLP and Dugan Law Firm APLC.

Figures

Figure 1.
Figure 1.
Data request eligibility by platform.

Similar articles

References

    1. Medicine Io. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Washington, DC: The National Academies Press, 2015, p.304. - PubMed
    1. Ohmann C, Banzi R, Canham S, et al. Sharing and reuse of individual participant data from clinical trials: principles and recommendations. BMJ Open 2017; 7: e018647. - PMC - PubMed
    1. Kiley R, Peatfield T, Hansen J, et al. Data Sharing from Clinical Trials — A Research Funder’s Perspective. N Engl J Med 2017; 377: 1990–1992. - PubMed
    1. The World Health Organization. Developing Global Norms for Sharing Data and Results during Public Health Emergencies, http://www.who.int/medicines/ebola-treatment/data-sharing_phe/en/ (2015). - PMC - PubMed
    1. 2023 NIH Data Management and Sharing policy, https://oir.nih.gov/sourcebook/intramural-program-oversight/intramural-d... (2023).

MeSH terms

LinkOut - more resources